A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study

BACKGROUND: The Gruppo Oncologico Italia Meridionale 9902 trial compared four cycles of high-dose epirubicin plus cyclophosphamide (EC) with four cycles of docetaxel (Taxotere, D) followed by four cycles of EC as adjuvant treatment of node-positive breast cancer. PATIENTS AND METHODS: Patients were...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Vici, P., Brandi, M., Giotta, F., Foggi, P., Schittulli, F., Di Lauro, L., Gebbia, N., Massidda, B., Filippelli, G., Giannarelli, D., Di Benedetto, A., Mottolese, M., Colucci, G., Lopez, M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2012
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3362268/
https://ncbi.nlm.nih.gov/pubmed/21965475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdr412
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky